Institut Jules Bordet, Université Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Brussels, Belgium.
Crit Rev Oncol Hematol. 2010 Aug;75(2):110-21. doi: 10.1016/j.critrevonc.2009.11.003. Epub 2009 Dec 9.
Due to improvements in diagnosis and systemic therapy, brain metastases are an increasingly common cause of morbidity and mortality for patients with advanced breast cancer. The incidence of symptomatic brain metastases among women with metastatic breast cancer ranges from 10% to 16%. The HER2 receptor, which is overexpressed in approximately 25% of all breast cancers, is an important risk factor for the development of central nervous system metastases. Surgery and radiation therapy are the primary approaches to the treatment of brain metastases but new chemotherapy and biological agents promise to play an important role in the future management of central nervous system disease. This article reviews the epidemiology, current treatment options and recent advances in the field, with a focus on HER2-positive disease and the emerging role of lapatinib for the treatment and prevention of brain metastases.
由于诊断和系统治疗的改进，脑转移是晚期乳腺癌患者发病率和死亡率日益增加的一个原因。在患有转移性乳腺癌的女性中，有症状的脑转移发生率在 10%至 16%之间。大约 25%的所有乳腺癌中过表达的 HER2 受体是中枢神经系统转移发展的一个重要危险因素。手术和放射治疗是治疗脑转移的主要方法，但新的化疗和生物制剂有望在中枢神经系统疾病的未来管理中发挥重要作用。本文综述了流行病学、当前的治疗选择和该领域的最新进展，重点关注 HER2 阳性疾病和拉帕替尼在治疗和预防脑转移中的新作用。
